title: Letter from the editor.
authors.affiliation: Senior Vice President R&D and Chief Technology Officer; NasVax, Ltd.; Ness Ziona, Israel.
authors.forename: Ronald
authors.initials: R
authors.lastname: Ellis
authors.affiliation: Acquisitions Editor; Landes Bioscience; Vienna, Austria.
authors.forename: Eva M
authors.initials: EM
authors.lastname: Riedmann
mesh_terms: D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D016780:Malaria, Vivax / Q000276:immunology / Q000517:prevention & control*; D013274:Stomach Neoplasms / Q000628:therapy*; D014612:Vaccines / Q000008:administration & dosage / Q000009:adverse effects* / Q000276:immunology*; D014777:Virus Diseases / Q000276:immunology / Q000517:prevention & control*
chemical_list: D014612:Vaccines